Strontium Chloride Sr-89 (Metastron)

Aetna covers strontium‑89 (Metastron) only for relief of bone pain from malignant bone metastases (including continuation if previously authorized and tolerated); all other uses—including cancer without bone involvement or pain from soft‑tissue tumors—are experimental/investigational and it is contraindicated in DIC. Key requirements: documented malignancy with bone metastases per Aetna criteria, pre‑treatment labs with WBC generally >2,400–3,000/µL and platelets >40–100 ×10^9/L (caution if platelets <60 ×10^9/L or WBC <2,400/µL), repeat dosing usually not sooner than 90 days, and appropriate ICD‑10/HCPCS coding.

"Relief of bone pain in members with a malignant/cancer diagnosis who have bone metastases (Aetna criteria for initial approval: both conditions required)."

Sign up to see full coverage criteria, indications, and limitations.